Sverige - svenska - Läkemedelsverket (Medical Products Agency)

agb-pharma ab - melatonin - tablett - 5 mg - mannitol hjälpämne; melatonin 5 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiska medel - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

agb-pharma ab - melatonin - tablett - 0,5 mg - melatonin 0,5 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

agb-pharma ab - melatonin - tablett - 3 mg - melatonin 3 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

agb-pharma ab - melatonin - tablett - 4 mg - melatonin 4 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

agb-pharma ab - melatonin - tablett - 1 mg - mannitol hjälpämne; melatonin 1 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

agb-pharma ab - melatonin - tablett - 2 mg - mannitol hjälpämne; melatonin 2 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

agb-pharma ab - melatonin - tablett - 5 mg - melatonin 5 mg aktiv substans; mannitol hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiska medel - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - antineoplastiska medel - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.